Alerta

METHOD OF DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MONOHORMONAL CELLS

Resumen de: US20260201339A1

0000 Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.

INSULIN PEN-TYPE SYRINGE REFRIGERATION CUP

Resumen de: US20260199610A1

0000 An insulin pen-type syringe refrigeration cup is provided, which is provided with an insulin pen cartridge. The insulin pen-type syringe refrigeration cup includes a refrigeration component, a cold conduction tube, a cup lid, and a cup body. The cold conduction tube defines a storage space that accommodates insulin pens, the storage space is also suitable for accommodating the insulin pen cartridge. A diameter of the cold conduction tube is 20 mm-50 mm. The cold conduction tube includes an avoidance groove. The cup lid is suitable for accommodating the refrigeration component. The cup body includes a cup wall and an insulation chamber. The cup lid can detachably seal the insulation chamber, and the refrigeration component keeps the insulation chamber in a low temperature state. The present disclosure significantly reduces the volume by limiting the size of the cold conduction tube and providing the avoidance groove.

METHOD OF INDUCING UMBILICAL CORD MESENCHYMAL STEM CELLS TO DIFFERENTIATE INSULIN-LIKE CELLS AND AN APPLICATION THEREOF

Resumen de: US20260201338A1

A method of inducing umbilical cord mesenchymal stem cells to differentiate insulin-like cells and an application thereof, the invention carries out reasonable culture of purified umbilical cord mesenchymal stem cells by adopting culture medium having different substances, and can efficiently and stably induce them to differentiate into insulin-like cells, and the percentage of insulin-positive cells can reach 80%. The cell preparation prepared after induction of umbilical cord mesenchymal stem cells of the invention can be used for the treatment of clinical diabetic patients with high therapeutic efficacy.

MACHINE LEARNING MODELS FOR DETECTING OUTLIERS AND ERRONEOUS SENSOR USE CONDITIONS AND CORRECTING, BLANKING, OR TERMINATING GLUCOSE SENSORS

Resumen de: US20260204414A1

Techniques disclosed herein relate to sensor data. In some embodiments, the techniques may involve obtaining sensor data. The techniques may further involve applying, to the sensor data, a machine learning model trained to identify outlier measurements. The techniques may further involve determining, based on output from the machine learning model, that the sensor data corresponds to an outlier measurement. The techniques may further involve blanking the sensor data based on the output.

WEARABLE DUAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS FOR PRECISION DIABETES MANAGEMENT

Resumen de: US20260199601A1

0000 A wearable dual closed-loop insulin delivery system is provided that integrates both a chemical closed-loop and an electronic closed-loop for precise glycemic control. The system includes a continuous glucose monitor (CGM) configured to obtain real-time blood glucose concentrations of a subject, and a glucose-responsive insulin (GRI) delivery device containing a GRI formulation that autonomously modulates its insulin-release rate in response to the subject's glucose levels, thereby forming a chemical closed-loop. The system further includes a controller having one or more computer processors executing a machine-learning adaptive glucose forecasting model with an Encoder-Decoder architecture. The model receives real-time glucose measurements from the CGM, predicts glycemia dynamics for at least a time period (i.e., 30 minute) future interval, and generates dosing-control signals to adjust both insulin-dosing amount and timing, forming an electronic closed-loop. The controller is operatively connected to the CGM and the GRI delivery device, enabling predictive, automated insulin regulation.

BLOOD GLUCOSE MANAGEMENT METHOD, USER INTERFACE, AND RELATED APPARATUS

Resumen de: US20260204390A1

0000 A blood glucose management method, a user interface, and a related apparatus are provided. According to one example of the blood glucose management method, a first meal time can be determined based on historical blood glucose values of a user; a second meal time can be determined based on one or more of the following: a meal time input by the user, a hand movement of the user, and a heart rate of the user; and a third meal time can be determined based on the first meal time and the second meal time, where the third meal time is used to evaluate a blood glucose health status of the user.

GLUCOSE LEVEL INDICATOR MODEL WITH MODIFIED ERROR RATE

Resumen de: US20260198867A1

A system is described herein comprising at least one application running on one or more processors of a server, wherein the at least one application is communicatively coupled with one or more sensor devices and a remote mobile device, the one or more sensor devices configured to monitor real time biometric data of a subject, the one or more sensing devices configured to transmit the real time biometric data to the at least one application, the at least one application configured to extract feature data variables from the real time biometric data, apply a predictive model to the feature data variables to predict glucose levels of the subject over a future period of time, and communicate a signal to the mobile device when predicted glucose levels cross either an upper or lower threshold.

INDUCTIVE CHARGING OF AN INFUSION PUMP

Resumen de: US20260199590A1

A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.

Smart Footwear, Insoles or Other Wearables with Electronically Read Sensing Membrane and Self-Identification of Left/Right Status

Resumen de: US20260198800A1

Wearable smart devices are disclosed that incorporate a unique means of detecting or measuring a substance of interest, for example to detect ammonia in the secreted foot sweat of a diabetic via incorporation of the sensing arrangement in a footwear article or insole. The setup employs the combination of a colour-changing sensing membrane responsive to the substance of interest, an optical sensor appropriately positioned to capture the membrane within its field of view, and an illumination means for illuminating the membrane to enable optical imaging thereof, from which a controller can then detect the colour of the membrane and determine the presence or measurement of the substance of interest. A left/right self-identification circuit is included in each wearable smart device to enable a cooperative pair of such devices, worn on different bilateral appendages, to self-identify their left/right designation to the external device that receives the outputted signals from the wearables.

LINEAR TIME-VARYING MODEL PREDICTIVE CONTROL OF AN ARTIFICIAL PANCREAS WITH BLOOD GLUCOSE PREDICTORS

Resumen de: WO2025054131A1

A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.

ADVANCED CONTINUOUS ANALYTE MONITORING SYSTEM

Nº publicación: EP4776527A2 15/07/2026

Solicitante:

DEXCOM INC [US]
DexCom, Inc.

Resumen de: EP4776527A2

The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor 10, such as a glucose sensor. In some embodiments, the continuous analyte sensor system 8 comprises a sensor electronics module 12 that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor 10 can be physically connected to a sensor electronics module 12, which is in direct wireless communication with a plurality of different display devices 14, 16, 18, and/or 20.